Skip Navigation

European Heart Journal 1983 4(Supplement C):93-100; doi:10.1093/eurheartj/4.suppl_C.93
Copyright © 1983 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Opie, L. H.
Right arrow Articles by Gordon, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Opie, L. H.
Right arrow Articles by Gordon, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1983 The European Society of Cardiology

Calcium antagonists and the acutely ischemic heart: experimental effects on ventricular fibrillation and enzyme release

L. H. Opie*,, F. T. Thandroyen*, C. W. Hamm*, C. A. Muller*, E. A. Lloyd{dagger} and D. Gordon{dagger}

* MRC-UCT Ischaemic Heart Disease Research Unit, Department of Medicine, Groote Schuur Hospital and University of Cape Town South Africa
{dagger} Cardiac Clinic, Groote Schuur Hospital Cape Town, South Africa

Requests for reprints to L. H. Opie, M.D., Heart Research Unit, University of Cape Town Medical School, Observatory 7925, Cape, South Africa

To investigate and to compare the protective action of verapamil, nifedipine and diltiazem on the acutely infarcting myocardium, we studied effects on cellular damage and mechanical function in the isolated working rat heart preparation subjected to left main coronary artery ligation. First, the fall in the ventricular fibrillation threshold (VFT) was diminished by all three agents, but non-specific effects of these agents were operating at least in part. All three compounds afforded substantial dose-dependent reduction of lactate dehydrogenase release, which was taken as an index of cellular damage, and preserved ATP stores in the infarcting myocardium. The range of effective concentrations was small and close to doses which produced atrioventricular conduction disturbances (verapamil, diltiazem) or LV pump failure (nifedipine). It is argued that these concentrations may be therapeutically relevant, whereas the concentration of a β-adrenoceptor antagonist agent required comparably to inhibit enzyme release was supra-therapeutic (metoprolol 10–4M). There are substantial differences between such animal models and the situation in acute myocardial infarction in man, where preliminary data show benefits both forβ-adrenergic blockade by sotalol and for calcium antagonism by nifedipine.

Key Words: Calcium antagonists • acute myocardial ischemia • ventricular fibrillation • enzyme release • verapamil • nifedipine • diltiazem • sotalol • acute myocardial infarction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991.
[Full Text] [PDF]

Home page
 NEJMHome page
L. Monserrat, M. Penas-Lado, A. Castro-Beiras, K. Iqbal, N. A. Tramboo, K. Mohi-Ud-Din, D. M. Spevack, M. S. Maron, I. Olivotto, and B. J. Maron
Hypertrophic Cardiomyopathy and Outflow Tract Obstruction
N. Engl. J. Med., May 1, 2003; 348(18): 1815 - 1816.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
H. Kuhn, F.H. Gietzen, M. Schafers, M. Freick, B. Gockel, C. Strunk-Muller, E. Jachmann, and O. Schober
Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion
Eur. Heart J., December 2, 1999; 20(24): 1808 - 1817.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.